Compare HKD & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HKD | OVID |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 479.4M |
| IPO Year | 2021 | 2017 |
| Metric | HKD | OVID |
|---|---|---|
| Price | $1.02 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.15 |
| AVG Volume (30 Days) | 118.2K | ★ 2.3M |
| Earning Date | 10-23-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $1.18 | $1.26 |
| 52 Week High | $2.14 | $3.11 |
| Indicator | HKD | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 14.63 | 41.03 |
| Support Level | N/A | $2.12 |
| Resistance Level | $1.76 | $2.67 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 2.27 | 4.30 |
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.